Peptide Stack Analyzer Tool Peptide Directory Peptide Discussion Forum Peptide Tools: Stacker & Calculators Trusted Vendors + Vendor Red Flags
Labels

TB-500 Peptide: Dosage, Reconstitution, and Recovery Protocol

TB-500 Peptide

TB-500 is a synthetic peptide derived from the LKKTETQ active region of Thymosin Beta-4 (Tβ4), a naturally occurring peptide involved in cell migration, tissue repair, and inflammatory signaling. TB-500 is commonly discussed in recovery and tissue-repair research, but it is not the same as full-length Thymosin Beta-4, and direct human evidence for TB-500 remains very limited.

How TB-500 Works

Actin Regulation → Cell Migration → Tissue Repair → Reduced Inflammation

TB-500 supports actin regulation and cellular migration, allowing repair cells to move efficiently to damaged tissues. This makes it especially useful during injury recovery phases rather than as a continuous-use peptide.

Regulates actin, a key protein involved in cellular movement
Supports cell migration toward damaged tissue
May improve circulation and angiogenesis in repair pathways
Acts more systemically than localized repair peptides like BPC-157
Typical Research-Use Protocol
Loading Phase → Reassess → Maintenance If Needed → Break
Standard Setup
Vial 10 mg
Water 3.0 mL bacteriostatic water
Concentration 3.33 mg/mL
Conversion 1 unit = 33.3 mcg
Loading Phase
Weeks 1–4
Dose 2–2.5 mg
Units 60–75 units
Frequency 2× weekly
Initial Duration 4 weeks
Reassess at the end of week 4 before automatically continuing.
Optional Loading Extension
Weeks 5–6
Dose 2–2.5 mg
Frequency 2× weekly
When to Extend If recovery is progressing but incomplete
The loading phase does not need to continue to 6 weeks if the original recovery goal has already been met.
When to Move to Maintenance
Reassess First
Consider maintenance only after the initial 4–6 week loading phase.
Move to maintenance when recovery has clearly improved but continued lower-frequency support is still desired.
If the recovery goal has been met, stop and begin a break instead of automatically continuing.
If there has been little or no improvement, reassess the underlying injury rather than simply extending the cycle indefinitely.
Optional Maintenance Phase
Only If Needed
Dose 2–4 mg weekly
Units 60–120 units
Frequency Once weekly
Duration Up to 4–8 additional weeks
Important:
Maintenance is not an automatic second phase. The clearer structure is: run the initial loading period, reassess recovery, then either stop, extend loading briefly, or transition to lower-frequency maintenance if the goal is still active.
Injury-Focused Recovery Protocol
Active Injury → Focused Recovery Period → Reassess Function → Stop When Recovery Goal Is Met
Separate Recovery Framework
This is a separate injury-focused framework, not the next phase after standard maintenance.
It is intended for periods of active tendon, ligament, muscle, or other soft-tissue recovery.
Because direct human TB-500 dosing evidence is limited, this should be labeled as a research/community-use framework rather than a clinically validated protocol.
Injury Recovery Range
Active Recovery
Dose 4–5 mg weekly
Units 120–150 units
Frequency Once weekly
Reassessment Every 2–4 weeks
Stop Point When the active recovery goal is complete
What to Reassess
Pain and soreness
Mobility and range of motion
Ability to tolerate normal training or activity
Tendon, ligament, or muscle function
Whether continued peptide use is still necessary
Keep this separate: Do not present injury recovery as “Loading → Maintenance → Injury Dose.” It should appear as its own option for an active injury, with its own reassessment and stopping point.
Reconstitution & Dosing (10 mg Vial)
Vial10 mg
Water3.0 mL bacteriostatic
Concentration3.33 mg/mL
Conversion1 unit = 0.01 mL ≈ 33.3 mcg
Common Dose Conversions
2 mg = 60 units (0.60 mL)
2.5 mg = 75 units (0.75 mL)
4 mg = 120 units (1.20 mL)
5 mg = 150 units (1.50 mL)
Reconstitution Steps
Clean vial tops with alcohol
Draw 3.0 mL bacteriostatic water
Inject slowly down the vial wall
Gently swirl, do not shake
Allow powder to fully dissolve
Label with the reconstitution date
Refrigerate immediately after mixing
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C / 36–46°F
Long-term storage: freeze at −20°C / −4°F
Estimated refrigerated shelf life: commonly ~12–24 months when sealed, dry, and protected from light
Estimated frozen shelf life: commonly up to ~2–3 years when stored properly
Keep sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Do not repeatedly freeze and thaw the same vial
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C / 36–46°F
Best used within 4–6 weeks
Use sooner for maximum potency
Do not freeze after mixing
Discard if cloudy, discolored, or if particles appear
Best Practice
TB-500 should be kept cold and protected from light. Once mixed, label the vial with the date and avoid repeated warming cycles.
Cycle Strategy & Time Between Cycles
Loading → Reassess → Maintenance If Needed → Break → Repeat Only If Needed
Standard Recovery Cycle
Initial Loading 4 weeks
Optional Extension Up to 6 weeks total
Maintenance Optional 4–8 weeks
Maintenance Trigger Improved but incomplete recovery
When to Stop Instead of Maintain
Recovery goal has been achieved.
Normal activity or training has returned.
Continuing no longer has a clear recovery purpose.
No meaningful improvement is occurring and the injury needs reassessment.
Time Between Cycles
Suggested Break 4–8 weeks
Use the break to assess whether improvements remain without continued dosing.
Repeat only if a new or unresolved recovery goal exists.
Avoid treating TB-500 as indefinite continuous maintenance.
Simple cycle logic: Start with 4 weeks of loading. Reassess. Extend to 6 weeks only if needed. If progress is good but incomplete, maintenance can follow. If recovery is complete, stop and take a break.
Monitoring During Use
Injury healing progress
Tendon, ligament, or muscle recovery
Inflammation and soreness
Mobility and flexibility
Training recovery and tissue tolerance
Injection site tolerance
Potential / Studied Benefits
Studied for its role in cell migration and tissue-repair pathways
May support tendon, ligament, and muscle repair mechanisms
Studied for inflammatory signaling and wound-healing pathways
May support angiogenesis and cellular migration involved in repair
Potential role in tissue remodeling and recovery
Potential Side Effects
Mild injection site irritation
Temporary fatigue, rare
Headache, uncommon
Mild soreness or swelling at injection site
Limited long-term human data
Stacking Strategies
TB-500 → Systemic Healing
BPC-157 → Localized Repair
GHK-Cu → Tissue Remodeling
Common Pairing Approaches
Recovery Stack: TB-500 + BPC-157
Advanced Healing: TB-500 + BPC-157 + GHK-Cu
Performance Recovery: TB-500 + BPC-157 + IGF-1, advanced only
Stacking Logic
TB-500 supports systemic healing and cell migration.
BPC-157 is often discussed for more localized repair signaling.
GHK-Cu may support tissue quality, collagen, and remodeling pathways.
Together, these target multiple layers of recovery.
Simple rule
TB-500 is the systemic recovery piece. BPC-157 is the localized repair piece. GHK-Cu adds tissue remodeling support when the goal is broader healing quality.
Important Notes
TB-500 is usually discussed for injury and recovery phases
It is not typically treated as a continuous daily peptide
Systemic effect makes injection location less specific than BPC-157
Loading and maintenance phases are commonly discussed
Human Evidence: Direct human clinical evidence for TB-500 is extremely limited. Human trials involving Thymosin Beta-4 generally studied full-length Tβ4, which is not interchangeable with the TB-500 fragment.
Recovery progress should be tracked over the full cycle

Important Disclaimer

TB-500 is an investigational peptide and not FDA-approved. This content is for educational purposes only.

Research & References

Primary Research

Research Note: The research base above concerns full-length Thymosin Beta-4, the endogenous peptide from which TB-500 (a synthetic fragment) is derived. Direct human clinical evidence specific to TB-500 remains very limited, and TB-500 is not FDA-approved for any indication.
TB-500 Guide → Peptide Directory →
Email Post
Similar Links:

Comments

Post a Comment